Kukje Pharma Co., Ltd. (KRX:002720)
4,625.00
-5.00 (-0.11%)
At close: Sep 15, 2025
Kukje Pharma Revenue
Kukje Pharma had revenue of 45.02B KRW in the quarter ending June 30, 2025, with 19.60% growth. This brings the company's revenue in the last twelve months to 167.81B, up 17.68% year-over-year. In the year 2024, Kukje Pharma had annual revenue of 156.46B with 15.58% growth.
Revenue (ttm)
167.81B
Revenue Growth
+17.68%
P/S Ratio
0.56
Revenue / Employee
676.66M
Employees
248
Market Cap
93.36B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 156.46B | 21.09B | 15.58% |
Dec 31, 2023 | 135.37B | 8.79B | 6.94% |
Dec 31, 2022 | 126.58B | 6.84B | 5.71% |
Dec 31, 2021 | 119.75B | -10.65B | -8.17% |
Dec 31, 2020 | 130.39B | 19.27B | 17.34% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |